Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Semaglutide protects the heart even in people without diabetes
Yes, certain GLP-1 receptor agonists (liraglutide, injectable semaglutide and dulaglutide) have demonstrated cardiovascular benefits in major trials, including reduced risk of heart attack, stroke and cardiovascular death in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
Clinical data suggests tirzepatide produces slightly more weight loss on average, but semaglutide is less expensive and has a longer track record
The discontinuation was a business decision, and not due to safety or efficacy issues
US$ 26.72
US$ 29.20
US$ 20.51
US$ 27.25
